Currently, several ongoing clinical trials are testing small drugs to activate Nrf2 in AD (e.g., NCT02292238; NCT02711683; NCT02085265; NCT04213391, Table 1) and some preliminary positive results are coming online [104]. Here, NFE2L2 is linked to Alzheimer disease.